Biochemistry & Analytical Biochemistry

Motohiro Morioka

Publications

• Short Communication
  Potential Benefit of Uric Acid for Thrombolytic Therapy in Acute Ischemic Stroke
  Author(s): Kiyoshi Kikuchi, Motohiro Morioka, Yoshinaka Murai and Eiichiro Tanaka Kiyoshi Kikuchi, Motohiro Morioka, Yoshinaka Murai and Eiichiro Tanaka
  
  Alteplase (recombinant tissue plasminogen activator) is the only licensed drug for acute ischemic stroke (AIS) treatment, but only 3–5% of patients with AIS receive thrombolytic treatment using alteplase. Further breakthroughs are needed for thrombolysis in AIS because thrombolytic therapy does not benefit all patients equally. Alteplase administration can induce intracerebral hemorrhage or a low rate of recanalization for occlusion of major cerebral arteries (e.g., internal carotid artery). Recently, the effect of alteplase–uric acid (UA) combination therapy was demonstrated in a clinical trial of AIS patients. UA administration resulted in a significant improvement in functional outcome in patients with hyperglycemia, female patients, and patients who had suffered a moderate stroke. Oxidative stress and antioxidant properties would be differ in each AIS patients after re.. View More»
  DOI: 10.4172/2161-1009.1000250

  Abstract PDF